Move reflects Delle Donne’s commitment to support and grow Delaware’s early-stage life sciences community
NEWARK, DE – April 27, 2018 – Delle Donne and Associates (DDA) and Delaware Bio Association (Delaware Bio) today announced that effective June 2018, Delaware Bio, currently located in Newark, Delaware, will move its headquarters to the former AstraZeneca North Campus, acquired by DDA in June 2017.
Ernest F. Delle Donne, Chairman of DDA, said, “DDA is committed to supporting and growing Delaware’s emerging life sciences community. We have a similar project on 16 acres within the University of Delaware's Science, Technology and Advanced Research Campus (STAR) in Newark. Through our work there, we have seen first-hand how necessary it is to surround high-tech and scientific start-ups with appropriate resources such as affordable lab and office space, educational services, professional mentoring, and other amenities. We believe the presence of Delaware Bio on our new property will serve as a great resource for these emerging, and typically fast-growing, life science businesses.” Helen Stimson, President, and CEO of Delaware Bio said, “As a connector organization, collaboration is critical to our success. Our decision to relocate to this new location supports our objective to work with multiple organizations, groups, and individuals who share our focus on creating a cohesive and complete offering for bioscience start-ups. “In our new facility, we will have the ability and the space to offer more resources to our members including high-content educational seminars to support aspiring entrepreneurs, hot desks and conference rooms for emerging life science businesses, and a professional, centrally located a place to network and evolve future alliances.”
Michael Bowman, Associate Director Office of Economic Innovation and Partnerships at the University of Delaware, said, "Collaborative efforts are needed to ensure that young life science companies are properly supported and it is gratifying to see DDA and Delaware Bio combine forces to better support and accelerate growth within the biopharma sector. “Importantly, Delaware Bio’s expanded headquarters will enable us to establish a satellite office within their new location and provide hands-on training for federal grant proposals, specifically SBIR and STTR programs, and much-needed business advisory services to support more efficient access to capital.” Delle Donne said, “Ultimately, the goal is to demonstrate Delaware’s commitment to start, nurture and grow early-stage life sciences companies. The benefits to Delaware are clear - more good jobs and a strong economy.”
About the Property
In June of 2017, Delle Donne and Associates purchased the former AstraZeneca North Campus in Fairfax. Simultaneous with the sale, AstraZeneca signed a long-term lease agreement for two buildings on the 80-acre campus. The campus is approved for another 900,000 square feet of development, and DDA additionally will be looking to add amenities that will help serve the surrounding 11,000 employment base. The Delaware Bio 3,500 square foot facility is strategically located on the campus entrance facing Concord Pike.
About Delle Donne and Associates
Delle Donne & Associates (DDA) is a Delaware corporation started over 70 years ago by Eugene A. Delle Donne. Ernest F. Delle Donne, Chairman, has assembled a creative team that takes pride in the quality of its product. Partners of the firm have extensive experience in real estate development, economic development, financial structuring and real estate law. DDA stresses a team approach to ensure adherence to the highest standards of quality, efficiency and personal commitment to every project. For additional information please go to https://dda1.com.
About Delaware BioScience Association
The mission of the Delaware BioScience Association is to become the catalyst to ensure Delaware becomes a leader in life sciences by developing a cohesive community that unites the region's biotechnology, pharmaceutical, research, financial and agricultural strengths. To accomplish this, Delaware Bio is committed to working collaboratively across the region to grow the life sciences industry.
Delaware's bioscience industry is helping to diversify and grow the U.S. economy. Coupled with its neighboring states of Pennsylvania and New Jersey, the tri-state region represents 80% of the US pharmaceuticals industry. Strong academic research institutions working collaboratively with medical institutions and industry develop and commercialize many of the blockbuster drugs and the most innovative diagnostics and medical devices found anywhere in the world. All within a 50 mile radius and within a one to two hour drive of each other. Global bioscience industry giants with significant Delaware research and or manufacturing operations include Agilent Technologies, AstraZeneca Pharmaceuticals, DuPont, Johnson & Johnson, Merck, Siemens Healthcare Diagnostics, W.L. Gore and within an hour's commute include Cephalon, Centocor, CSL Behring, Endo Pharmaceuticals, GSK, Pfizer, Sanofi-Aventis and more.
For additional information please go to http://delawarebio.org
Eugene A. Delle Donne
DelleDonne Associates, Inc.
302 325 1111 x 128
President and CEO
Delaware BioScience Association